Home

14159, L.P.

CIK 1551138 · last filed 2019-02-27

14159, L.P. is a corporate insider who has filed 22 SEC Form 4 insider transactions across 8 companies since 2012. The most recent filing shows the insider exercised options covering $784.0K of INCY on Feb 27, 2019. Across all open-market trades the lifetime net is +$899.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $684.0M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$684.04M

Companies

8

Total Filings

22

Lifetime Open-Market Net

$899.93M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
INCY Director 92,042 $117.98 $10.86M $0 6 2019-02-27
Aceragen, Inc. (IDRA) Delisted Director 251,992 $7.22 $1.82M $0 2 2019-01-04
ACAD Director 24,667,110 $25.25 $622.84M $459.53M 2 2018-09-24
GENOMIC HEALTH INC (GHDX) Delisted Director 204,452 — — $223.55M 7 2017-10-03
XOMA Director 870,308 $40.17 $34.96M -$92.18M 2 2014-12-10
Seagen Inc. (SGEN) Delisted Director 3,949,073 $228.74 $903.31M $113.02M 1 2013-12-16
BCRX 10%+ Owner 1,642,513 $9.36 $15.37M $50.00M 1 2013-08-02
SYNAGEVA BIOPHARMA CORP (GEVA) Delisted Director 207,820 — — $146.01M 1 2012-07-13

Recent Filings

22 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2019-02-27 INCY Exer (M) +280,000 $784.0K EDGAR
2019-01-04 Aceragen, Inc. (IDRA) Delisted Grant (A) +76,818 $270.4K EDGAR
2018-09-24 ACAD Buy (P) +8,475,432 $158.53M EDGAR
2018-04-02 INCY Grant (A) +4,788 $399.0K EDGAR
2017-10-03 GENOMIC HEALTH INC (GHDX) Delisted Grant (A) +37,320 $1.20M EDGAR
2017-06-01 GENOMIC HEALTH INC (GHDX) Delisted Exer (M) +495,000 $8.97M EDGAR
2017-02-22 INCY Mixed +74,275,474 $0 EDGAR
2016-08-12 ACAD Buy (P) +9,121,210 $301.00M EDGAR
2015-10-05 GENOMIC HEALTH INC (GHDX) Delisted Grant (A) +56,160 $1.20M EDGAR
2015-10-05 INCY Grant (A) +3,612 $398.5K EDGAR
Showing 1–10 of 22
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.